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Chronic exposure to nicotine up-regulates high sensitivity nicotinic acetylcholine receptors (nAChRs) in the brain.
This up-regulation partially underlies addiction and may also contribute to protection against Parkinson’s disease.
nAChRs containing the 6 subunit (6* nAChRs) are expressed in neurons in several brain regions, but comparatively
little is known about the effect of chronic nicotine on these nAChRs. We report here that nicotine up-regulates 6*
nAChRs in several mouse brain regions (substantia nigra pars compacta, ventral tegmental area, medial habenula,
and superior colliculus) and in neuroblastoma 2a cells. We present evidence that a coat protein complex I (COPI)mediated process mediates this up-regulation of 6* or 4* nAChRs but does not participate in basal trafficking.
We show that 623 nAChR up-regulation is prevented by mutating a putative COPI-binding motif in the 3 subunit or by inhibiting COPI. Similarly, a COPI-dependent process is required for up-regulation of 42 nAChRs by
chronic nicotine but not for basal trafficking. Mutation of the putative COPI-binding motif or inhibition of COPI
also results in reduced normalized Förster resonance energy transfer between 623 nAChRs and COP subunits.
The discovery that nicotine exploits a COPI-dependent process to chaperone high sensitivity nAChRs is novel and
suggests that this may be a common mechanism in the up-regulation of nAChRs in response to chronic nicotine.
INTRODUCTION

One of the earliest discoveries of chronic nicotine exposure was the observation of an increased number of
nicotinic acetylcholine receptors (nAChRs; termed upregulation) (Marks et al., 1983; Schwartz and Kellar,
1983; Breese et al., 1997; Mamede et al., 2007; Nashmi
et al., 2007). Classically, up-regulation of nAChRs has
been defined as an increase in nAChR protein, as identified by increased agonist binding (Marks et al., 1983;
Benwell et al., 1988; Flores et al., 1992; Peng et al.,
1994), but we now define up-regulation as a change in
receptor number, stoichiometry, and trafficking (Lester
et al., 2009; Miwa et al., 2011). Often, an increase in
total binding as opposed to cell surface binding has
been reported. Therefore, up-regulation of nAChRs involves an increase in nAChR abundance throughout
the cell (ER, Golgi, etc.) and not exclusively on the
plasma membrane (PM). There have been several hypotheses regarding the mechanism of up-regulation,
but a consensus is emerging that nicotine acts inside the
cell to enhance a critical step(s) in the maturation process
Correspondence to Henry A. Lester: Lester@Caltech.edu
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of nAChRs (Sallette et al., 2005). This intracellular enhancement process has been characterized as pharmacological chaperoning (Kuryatov et al., 2005; Lester et al.,
2009), and it occurs at the nanomolar concentrations
thought to persist in the brain for hours after a person
smokes. Research from many laboratories indicates that
up-regulation of 42 nAChRs occurs through a similar
process in human brains, animal brains, cultured neurons, and clonal transfected cell lines (Nashmi et al.,
2007; Mukhin et al., 2008; Miwa et al., 2011; Srinivasan
et al., 2011; Lester et al., 2012).
Up-regulation of nAChRs in response to chronic nicotine plays a major role in nicotine dependence and,
perhaps, in the inverse correlation between a person’s
history of tobacco use and his or her susceptibility to
Parkinson’s disease (Ritz et al., 2007; Koob, 2009). Individual deletions of the 4, 6, or 2 nAChR subunits
are sufficient to block the self-administration of nicotine
in mice (Pons et al., 2008), whereas the selective reexpression of these deleted subunits in the ventral tegmental
area (VTA) is sufficient to reinstate self-administration
of nicotine (Pons et al., 2008; Brunzell et al., 2010).
© 2014 Henderson et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Furthermore, nicotine self-administration can be blocked
by the selective antagonism of 6* (*, IUPHAR nomenclature, “other subunits may be present”) (Jackson
et al., 2009) or 4* (Yoshimura et al., 2007) nAChRs.
From this, it is clear that the nAChRs mediating nicotine addiction include those that contain 4, 6, and 2
subunits (Picciotto et al., 1998; Tapper et al., 2004; Pons
et al., 2008).
Despite the clarity of 42 nAChR up-regulation,
there have been conflicting reports of up-regulation,
down-regulation, or no change in response to chronic
nicotine for 6* nAChRs (Tumkosit et al., 2006; Perez
et al., 2008; Walsh et al., 2008). Here, we used mice expressing 6–enhanced green fluorescence protein
(eGFP) nAChR subunits to test for in vivo up-regulation
of 6* nAChRs using concentrations of nicotine comparable to those produced by smoking in humans. We
determined that this up-regulation occurs in all four
brain areas that robustly express 6* nAChRs: the VTA,
the substantia nigra pars compacta (SNc), the medial
habenula, and the superior colliculus.
We then used 6 subunits tagged with superclipticpHluorin (SEP), a pH-sensitive eGFP analogue, expressed
in neuroblastoma cells to analyze the mechanism of 6*
nAChR up-regulation. SEP has been used to study vesicle dynamics and synaptic delivery (Miesenböck et al.,
1998; Mani and Ryan, 2009) as well as the trafficking of
AMPA and GABA receptors (Jacob et al., 2005; Jaskolski
et al., 2009; Lin et al., 2009; Araki et al., 2010), and we
have used 4-SEP* to study nAChR trafficking after
chronic exposure to nicotine (Richards et al., 2011).
Here, we show that nicotine-induced up-regulation fails
to occur with inhibition of coat protein complex I
(COPI)-mediated retrograde traffic from the Golgi to
the ER (either through the mutation of a putative
COPI-binding motif [3-KKK] or through the use of
the COPI inhibitor CI-976). COPI is a protein complex
that coats vesicles for retrograde transport of proteins
from the cis end of the Golgi to the ER (Brandizzi and
Barlowe, 2013). COPI is a heptameric protein complex, and di-lysine–trafficking motifs, including KKxx
and KxKxx, facilitate protein binding to COPI (Jackson
et al., 2012; Spang, 2013). Inhibition of COPI-mediated
trafficking resulted in a decrease of nAChR density in
the ER and a complementary increase of nAChR density in the Golgi. Inhibition of COPI had no effect on
basal insertion of nAChRs in the PM but prevented
their up-regulation during chronic nicotine treatment.
Therefore, we propose that the cycling of nAChRs between the Golgi and ER (via COPI) is necessary for the
up-regulation of 42 and 623 nAChRs. Our data
suggest that this may be a common mechanism of
nAChR up-regulation by nicotine, and that the manipulation of Golgi–ER cycling may lead to novel therapeutic
strategies for nicotine cessation or neuroprotection
against Parkinson’s disease.
52
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MATERIALS AND METHODS
Reagents
The -COP antibody (rabbit polyclonal) was obtained from Abcam
(AB2899). CI-976 and ()-nicotine hydrogen tartrate were obtained from Sigma-Aldrich.
Mice and chronic nicotine administration
The construction of 6-GFP mice has been described previously
(Mackey et al., 2012). All experiments were conducted in accordance with the guidelines for care and use of animals provided by
the National Institutes of Health, and protocols were approved by
the Institutional Animal Care and Use Committee at the California Institute of Technology.
Chronic nicotine administration
Mice were kept on a standard 12-h light/dark cycle at 22°C and
given food and water ad libitum. Chronic nicotine or saline was
administered to mice using miniosmotic pumps (model 2002;
Alzet). On the day of pump implantation, saline or ()-nicotine
hydrogen tartrate (Sigma-Aldrich) was prepared freshly and loaded
into the pump to deliver nicotine at 2 mg/kg/h or 0.4 mg/kg/h.
This concentration provides maximal nAChR up-regulation and a
peripheral blood concentration that is near the peak concentration found in the blood of human smokers (Marks et al., 2004).
Surgical procedures for the pump implantation have been reported previously (Nashmi et al., 2007).
Cell culture
Mouse neuroblastoma 2a (Neuro-2a) cells were cultured using
standard techniques (Xiao et al., 2011). Cells were plated by adding 90,000 cells to poly-d-lysine–coated 35-mm glass-bottom imaging dishes (MatTek Corporation) and cultured in a humidified
incubator (37°C, 95% air, 5% CO2). Cells were transfected with
500 ng of each nAChR subunit plasmid and 250 ng GalT-mCherry
or Sec24D-mCherry for assays. Plasmids were mixed with 250 µl
Opti-MEM. Lipofectamine-2000 was separately added to 250 µl
Opti-MEM. After 5 min at 24°C, DNA and Lipofectamine solutions were mixed together and incubated for 25 min at 24°C. The
solutions were then added to preplated Neuro-2a cells and incubated for 24 h. After 24 h, the Opti-MEM was removed and replaced with growth medium. 50 or 500 nM of filter-sterilized
nicotine was added after replacing the Opti-MEM with standard
culture medium (623 nAChRs). For 42 nAChRs, 100 nM
nicotine was used for 48 h (nicotine was added at the time of
transfection and then replenished when the media was changed).
20 µM CI-976 was added with nicotine 24 h before imaging. Cells
were imaged 48 h after transfection.
Patch-clamp recordings
For patch-clamp electrophysiology, 50,000 Neuro-2a cells were
plated onto sterilized 12-mm glass coverslips (Deckgläser), placed
in 35-mm culture dishes, and cultured in a humidified incubator
(37°C, 95% air, 5% CO2). Recorded cells were visualized with an
inverted fluorescence microscope (IX71; Olympus) in either bright
field or fluorescence (eGFP) mode using a high pressure Hg lamp
(HB-10103AF; Nikon). Electrophysiological signals were recorded
with an amplifier (Axopatch-1D; Axon Instruments), analogueto-digital converter (Digidata 1440A; Axon Instruments), and software (pClamp 10.0; Axon Instruments). Patch pipettes were filled
with solution containing (mM): 135 K gluconate, 5 KCl, 5 EGTA,
0.5 CaCl2, 10 HEPES, 2 Mg-ATP, and 0.1 GTP (pH was adjusted to
7.2 with Tris-base, and osmolarity was adjusted to 280–300 mOsm
with sucrose). The resistance of patch pipettes was 2–4 MΩ for
whole-cell recordings. Junction potential was nulled just before

forming a gigaseal. All recordings were done at 24°C. Data were
sampled at 10 kHz and filtered at 2 kHz for whole-cell recordings.
Acetylcholine was dissolved in extracellular solution containing
(mM) 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose (320 mOsm, pH set to 7.3 with Tris-base), and were puffed
(0.3 s, 20 psi) onto voltage-clamped Neuro-2a cells (holding potential [VH] of 50 mV). To avoid receptor desensitization by repetitive ACh application, we applied ACh at 3-min intervals and
continually perfused the recording chamber with extracellular
solution. For concentration response studies, we used a rapid superfusion system with 500-ms puffs of agonist (Octaflow II; ALA
Scientific Instruments).
Immunostaining and antibodies
For immunostaining, cultured Neuro-2a cells were fixed with 4%
paraformaldehyde (15 min), permeabilized in 0.01% Triton X-100
(5 min), and blocked with 10% goat serum (30 min). After two
PBS washes, the appropriate primary antibody (1:500) in 1% goat
serum was applied for 1 h at 24°C. Cells were washed three times
with PBS and incubated with 1% goat serum containing secondary antibody (1:2,000) for 1 h at 24°C. Cells were washed three
times with PBS and imaged immediately. Immunostaining used
-COP rabbit polyclonal antibody as the primary (antibody 2899;
Abcam) and Alexa Fluor 555–labeled secondary (goat anti–rabbit;
Invitrogen) antibodies.
Midbrain 6-GFP neurons existed in a high enough density to
be imaged without staining (direct/inherent fluorescence). Immunohistochemical techniques were required for observing 6GFP fluorescence in other regions of the mouse brain. 20-µm
brain sections on slides were rinsed twice for 10 min with PBS and
then permeabilized with 0.5% Triton X-100 in PBS for 1 h. Brain
sections were then blocked with 4% goat serum (Jackson Immuno
Research Laboratories, Inc.) in PBS for 45 min. The primary
antibody was diluted in 4% goat serum in PBS and incubated
overnight at 24°C. Brain sections were then washed three times
for 15 min with PBS, and the secondary antibody was diluted in
4% goat serum in PBS and incubated for 1 h at 24°C. Finally,
brain sections were washed three times for 15 min with PBS and
mounted with Vectashield.
Total internal reflection fluorescence microscopy (TIRFM)
Cultured Neuro-2a cells were imaged live at 37°C in a stagemounted culture dish incubator (Warner Instruments) using
methods similar to TIRFM assays in cultured cortical neurons
(Richards et al., 2011). TIRFM enables the visualization of fluorescently labeled intracellular molecules within 250 nm of the
cell-coverslip interface. TIRFM images were obtained using an inverted fluorescence microscope (IX81; Olympus) equipped with
a 100× 1.45 NA oil objective (PlanApo; Olympus) and a stepper
motor (Thorlabs) to control the position of the fiber optic and
TIRFM evanescent field illumination. Just before imaging, growth
medium was exchanged for extracellular solution (150 mM NaCl,
4 mM KCl, 10 mM HEPES, 2 mM MgCl2, 2 mM CaCl2, and 10 mM
glucose), adjusted to the appropriate pH (5.4 or 7.4). SEP was
excited at 488 nm with an air-cooled argon laser (IMA101040ALS;
Melles Griot). Images were captured with a back-illuminated
EMCCD camera (iXon DU-897; Andor). We acidified the imaging
dish by perfusing the bath, normally at pH 7.4, with an otherwise
identical solution adjusted to pH 5.4. The PM integrated density
(PMID) was determined by taking an initial TIRFM image of each
cell at pH 7.4, followed by acidification of the solution and a subsequent low pH image (pH 5.4). Low pH images were used to
demarcate ER-localized nAChRs, which were subtracted from the
total footprint to determine the PMID of nAChRs. The figures
show a single imaging session that is representative of at least
three sessions performed on separate days with similar or identical results.


Insertion events were quantified using methods similar to those
published previously (Richards et al., 2011). TIRFM measurements
to detect membrane insertion events were performed with consecutive 200-ms frames. Insertion events were defined as punctate
regions of fluorescence appearing at the membrane. Insertion
event data are represented in terms of insertion per 10 µm2 of area
per minute of observation.
Spectral confocal imaging
Imaging experiments were performed in live Neuro-2a cells at
37°C in a stage-mounted culture dish incubator (Warner Instruments). For immunostaining, fixed Neuro-2a cells were imaged. A
C1si laser-scanning confocal microscope (Eclipse; Nikon) equipped
with a 60× 1.2 NA VC Plan Apo water objective and 32 photomul
tiplier tubes was used for confocal imaging. Before an imaging
session, cell culture medium was replaced with phenol red–free
CO2-independent Leibovitz (L-15) medium (Invitrogen). eGFP
and mCherry were excited at 488 and 561 nm, respectively. For
each cell, we focused on a plane containing the most ER exit sites
(ERES), Golgi bodies, or COPI vesicles, and sequential images
of eGFP and mCherry fluorescence were obtained. eGFP and
mCherry fluorescence emission spectra were captured and images
were unmixed using standard spectra acquired from cells expressing eGFP, mCherry, or Alexa Fluor 555 alone. For quantification,
ERES, Golgi, or COPI regions of interest (ROI) were manually demarcated using intensity-based thresholding, and the raw integrated densities were measured for each cell using ImageJ. The
total Sec24D fluorescence in ERES and the total GalT fluorescence
per cell were quantified. Error bars for measurements indicate the
SEM, and p-values are based on a two-tailed t test. The figures show
a single imaging session that is representative of at least three sessions performed on separate days with similar or identical results.
For direct fluorescence imaging of in vivo 6-GFP* nAChRs,
images were acquired with the 60× 1.2 NA VC Plan Apo water
objective at wavelengths between 496 and 561 nm using a 488-nm
line of an argon laser. Images were collected at 12-bit intensity
over 512 × 512 pixels, a resolution of 2.5 nm, a 61.3-µm pinhole,
and a pixel dwell time of 8.4 µs. Autofluorescence was separated
from GFP fluorescence using techniques that have been published
previously (Nashmi et al., 2007). Image analysis of cell counts and
mean intensities were done with ImageJ.
Normalized Förster resonance energy transfer (NFRET)
The general methods for Förster resonance energy transfer from
sensitized acceptor emission have been described previously
(Srinivasan et al., 2011, 2012a). For these studies, Neuro-2a cells
were transfected with 6-mCherry, 2wt, COP-GFP, and 3wt or
3AAA nAChR subunits. Cells transfected with either 6-mCherry
or COP-GFP alone were included in all imaging sessions to control for pixel saturation and spectral bleedthrough. Live cells
were imaged with a C1si laser-scanning confocal microscope
(Eclipse; Nikon). During acquisition of images, cells were focused
on a plane where the COP-GFP fluorescence most resembled
the pattern for the endogenous COPI staining (see Fig. 4 E). GFP
and mCherry images were acquired with 488- and 561-nm laser
lines, and images were linearly unmixed by using reference spectra. Reference spectra were acquired from Neuro-2a cells transfected with 6-mCherry or COP-GFP during the same imaging
session. After linear unmixing, NFRET was calculated using the
PixFRET ImageJ plug-in as described previously (Moss et al.,
2009; Srinivasan et al., 2011, 2012a).
Plasmid constructs
Mouse 6 with a C-terminal fusion of an SEP tag was constructed
by PCR amplification using the forward primer 5-CATGGTTGG
CTGGTATGATCAGTAAAGGAGAAGAACTT-3 and the reverse
primer 5-ATGGATGAACTATACAAATAGGGAATAGCGGCACCT-3,
Henderson et al.
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which overlap with sequences within the C-terminal end of the
6-coding sequence. This PCR product was then cloned directly into
the vector containing the 6 gene using Pfu-Turbo polymerase.
The mouse 23 nAChR subunit was constructed by PCR amplification using the forward primer 5-ATGGCCCGGTGCTCCAACTC-3
and the reverse primer 5-CCTGCCCTCAGACTGTGGTG-3. The
mouse 32 nAChR subunit was constructed by PCR amplification
using the forward primer 5-ATGACAGGCTTCCTACGGGT-3 and
the reverse primer 5-ACGGTCCTGGTGTTCTACCT-3. Mouse
3AAA (the KKK mutated to AAA) and the 23[AAA] were constructed
by PCR amplification using the forward primer 5-AAATTTCCAG
GGGCTGCAGCCCAGACTCCTACC-3 and the reverse primer
5-CCCCCTCACGGTTCCCTTACTCTCCGT-3.
Online supplemental material
Fig. S1 illustrates that the presence of 3 subunits increased the
PMID of 64 nAChRs but is not required for the up-regulation
of 64* nAChRs. Fig. S2 presents a schematic of the various chimeras and mutant nAChR subunits that were used in this paper. Fig. S3
shows the electrophysiological characterization of 623WT and
623AAA nAChRs after treatment with nicotine. Here, we show
that functional up-regulation accompanies the increase in PMID
for 623WT nAChRs when treated with nicotine, but there is no
functional up-regulation with 623AAA nAChRs. Fig. S4 illustrates
that treatment with CI-976 produces an increase of nAChRs in the
Golgi but does not increase export from the ER. Fig. S5 shows
that CI-976 treatment does not affect basal PMID of nAChRs. The
online supplemental material is available at http://www.jgp.org/
cgi/content/full/jgp.201311102/DC1.

RESULTS
In vivo up-regulation of 6* nAChRs with chronic nicotine

We used a mouse line containing GFP-labeled 6*
nAChRs to study the up-regulation of 6* nAChRs
(Mackey et al., 2012). 6-GFP nAChR subunits assemble
appropriately with other nonlabeled nAChR subunits,
traffic properly, and function in electrophysiological assays in a manner comparable to that of WT nAChRs
(Mackey et al., 2012).
Direct fluorescence of 6-GFP* nAChRs was apparent
in the VTA and SNc of saline- or nicotine-treated mice
(Fig. 1 A). The fluorescence intensity of 6-GFP*
nAChRs in the VTA and SNc of mice administered nicotine at 2 mg/kg/h for 10 d was increased twofold compared with that of saline-treated mice (P < 0.005; Fig. 1,
B1 and C1). In addition, we used cumulative percentage
plots to compare saline and nicotine treatments (Fig. 1,
B2 and C2). Cumulative percentage plots are similar to a
cumulative frequency analysis and allow us to compare
the full range of 6-GFP fluorescence intensities between
saline and nicotine treatments. In all four brain regions,
we can see that the percentage of low, mid, and high
6-GFP fluorescence intensities are shifted to the right

Chronic nicotine upregulates 6-GFP* nAChRs in
four brain regions. (A) Direct
fluorescence imaging of SNc and
VTA in mice expressing 6-GFP
subunits after treatment with
saline or nicotine (2 mg/kg/h,
10 d). (D1 and E1) Immunohistochemical imaging of medial habenula and superior colliculus
in mice expressing 6-GFP subunits after treatment with saline
or nicotine. For all images, montages were compiled from individual 60× images. (A and E1)
Bars, 100 µm. (D1) Bars, 20 µm.
(B1 and C1) Quantification of 6GFP intensities in SNc and VTA
of saline- and nicotine-treated
mice (n = 6 mice). (D2 and E2)
Quantification of 6-GFP intensities in medial habenula and
superior colliculus of saline- and
nictotine-treated mice (n = 6
mice). (D3 and E3) Quantification of 6-GFP immunofluorescence of medial habenula and
superior colliculus neurons in
saline- and nicotine-treated mice
(n = 4–5 mice). (B2, C2, D3, and
E3) Cumulative percentage plots
show changes in 6-GFP fluorescence in all brain regions with
chronic nicotine. ***, P < 0.005;
*, P < 0.05.
Figure 1.
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(higher intensity) after chronic nicotine treatment (Fig. 1,
B2 and C2). Nicotine at 0.4 mg/kg/h also increased 6GFP fluorescence intensity in VTA (60.8 ± 10.9% increase)
and SNc (70.0 ± 1.4% increase) neurons (P < 0.05 compared with saline; Fig. 2). Similar to 2 mg/kg/h nicotine
treatments, the 0.4-mg/kg/h nicotine treatment shifted
the full range of 6-GFP fluorescence intensities to the
right in cumulative percentage plots (Fig. 2, D1 and D2).
2 mg/kg/h nicotine also increased the fluorescence
intensity of medial habenula and superior colliculus 6GFP* nAChRs (81% [P < 0.005] and 68% [P < 0.05],
respectively; Fig. 1, D and E). In cumulative percentage
plots, we can also see that the full range of 6-GFP fluorescence intensities is shifted to the left after chronic
nicotine treatment (Fig. 1, D1 and D2).
6-SEP* nAChRs assemble functional receptors, and 3
subunits increase 6* nAChR function

To perform a systematic study on 6* nAChR upregulation, we used an expression system, Neuro-2a
cells, which has been optimized to avoid many artifacts
of “overexpressing” PM proteins. The appearance of
functional PM proteins in this system is linear and unsaturated as a function of parameters such as level of
transfected cDNAs, trafficking machinery, oligomerization, and anchoring (Moss et al., 2009).
SEP undergoes 488-nm excitation at neutral pH
(7.4) but not under acidic conditions (Richards et al.,
2011). 6-SEP* nAChRs in the Golgi and secretory vesicles
(6.7 and <6.5 pH, respectively) are not fluorescent

(Asokan and Cho, 2002; Jaskolski et al., 2009). When exposed to a neutral buffer (pH 7.4) both ER- and
PM-resident nAChRs are fluorescent. Upon perfusing
an acidic buffer (pH 5.4), PM-resident nAChR fluorescence is quenched, whereas the ER component remains
fluorescent. Thus, SEP allows the differentiation of receptors within the ER from those in the PM. As in a
previous study using SEP tagged to 4 nAChRs (Richards et al., 2011), we fused SEP to the C terminus of 6
subunits so that it was positioned on the luminal side of
organelles in the secretory pathway.
nAChRs with eGFP subunits have little or no functional difference (i.e., peak current amplitude, decay
time) from WT subunits (Drenan et al., 2008; Richards
et al., 2011; Srinivasan et al., 2011, 2012b; Xiao et al.,
2011) and, indeed, we found no detectable functional
difference between 6-SEP23 nAChRs and 6eGFP23 nAChRs (Fig. 3). Inclusion of the 3 subunit increased ACh-induced peak currents by threefold
compared with those obtained with 6-eGFP2
nAChRs (Fig. 3 B; P < 0.05). Inclusion of the 3 subunit also reduced the concentration of ACh at which
we observed maximal peak amplitude from 300 µM
(6-eGFP2) to 3 µM (6-eGFP23) (Fig. 3). Concentration–response studies of ACh and ()-nicotine
on 6-eGFP23 nAChRs yielded EC50 values of 0.31 ±
0.10 µM and 0.12 ± 0.08 µM, respectively (Fig. 3, C and D),
which agree with those obtained with linked concatamers containing (62)23 nAChRs (Kuryatov and
Lindstrom, 2011).

Figure 2. Low concentrations of nicotine (0.4 mg/kg/h) up-regulate 6-GFP* nAChRs in midbrain neurons. (A and B) Direct fluo
rescence imaging of VTA and SNc neurons in mice expressing 6-GFP subunits after treatment with saline or nicotine (0.4 mg/kg/h,
10 d). Bars, 100 µm. (C1 and C2) Quantification of 6-GFP intensities of neurons in saline- or nicotine-treated mice (n = 4 mice).
(D1 and D2) Cumulative percentage plots show changes in 6-GFP fluorescence in the SNc and VTA with chronic nicotine (0.4 mg/
kg/h; n = 4 mice). *, P < 0.05.



Henderson et al.

55

Figure 3. The 6-SEP nAChRs are functional. Representative whole-cell ACh-induced currents of (A1) 6-SEP23 nAChRs (3 µM
ACh). (A2) 6-eGFP23 nAChRs (3 µM ACh) and (A3) 6-eGFP2 nAChRs (300 µM ACh). (B) Comparison of whole-cell ACh-induced
current amplitudes of 6-SEP23, 6-eGFP23, and 6-eGFP2 nAChRs (n = 7–11). (C) Concentration–response of ACh on 6eGFP23 nAChRs (n = 15). (D) Concentration-response of ()-nicotine on -eGFP23 nAChRs (n = 14). *, P < 0.05.

Incorporation of 3 subunits increases the density of 6*
nAChRs at the PM

We used TIRFM and 6-SEP* nAChRs transfected in
Neuro-2A cells to quantify the density of receptors in
the peripheral ER versus the PM. Fig. 4 A shows TIRFM
images of Neuro-2a cells expressing 6-SEP2 or 6SEP23 nAChRs at neutral (7.4) and acidic (5.4) pH.

As reported previously (Tumkosit et al., 2006), 623
nAChRs had a higher density on the PM than 62
nAChRs; the PMID of 623 nAChRs was three times
that of 62 nAChRs (P < 0.0001; Fig. 4 B). We also
found a 1.5-fold increase in the PMID of 643
nAChRs compared with that of 6-SEP4* nAChRs
(Fig. S1). We found that, when expressed in Neuro-2a

Figure 4. The 3 subunit in
creases the density of 6*
nAChRs at the PM and is necessary for the nicotine-induced
up-regulation of 62* nAChRs.
(A, C, and E) Representative
TIRFM images of Neuro-2a cells
transfected with 6-SEP and a
combination of 2 with or without 3 nAChR subunits at basic
(pH 7.4) and acidic (pH 5.4)
conditions. Nicotine was added
at listed concentrations 24 h
before imaging. (B, D, and F)
PMID for 6-SEP* nAChRs.
Bars, 10 µm (n = 19–23). Data are
mean values ± SEM. n.s., not significant; ***, P < 0.0001.
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cells, 6-SEP3 nAChRs resided almost entirely in the
ER (94.5 ± 2.2% ER localization; not depicted). Collectively, these data show that the 3 subunits, combined
with 2 or 4 nAChR subunits, increase the density of
6* nAChRs on the PM.
Confirmation that 3 subunits enhance nicotine-induced
up-regulation of 62* nAChRs

We next assessed the effect of chronic nicotine on 62*
nAChRs. We examined 6* nAChRs exposed to 50 or
500 nM nicotine for 24 h. 50- and 500-nM nicotine concentrations, respectively, mimic the steady-state and
peak concentrations of nicotine found in the brains of
smokers (Marks et al., 2004). 50 nM nicotine also equals
the plasma concentration produced by 14–21-mg nicotine patches (Schnoll et al., 2013). We observed a significant (P < 0.0001) increase in the PMID of 6-SEP23
nAChRs after treatment with 50 nM nicotine, but a significant (P < 0.0001) decrease in PMID after 500-nM
nicotine treatment (Fig. 4, C and D). 6-SEP2 nAChRs
showed no change in PMID after 50-nM nicotine treatment and a decrease in PMID after 500-nM nicotine
treatment (Fig. 4, E and F). 50 or 500 nM nicotine induced a greater than threefold increase in 6-SEP4*
nAChRs PMIDs in the presence or absence of the 3
subunit (Fig. S1).
Dynamic visualization of SEP nAChRs enables us to
see when nAChRs arrive at the PM, as they appear as a
region of punctate fluorescence (Richards et al., 2011;
Fig. 5, A and B1–3). We quantified the frequency of these
vesicular insertion events at the PM (Fig. 5). After exposure to 50 nM nicotine, we observed a threefold increase
in the insertion events of 6-SEP23 nAChRs (P < 0.05)
and no change in the insertion events of 6-SEP2

nAChRs (Fig. 5, C and D). These data correlated with the
observed nicotine-induced changes of PM intensities
for 6-SEP23 and 6-SEP2 nAChRs. Specifically, we
note a similarity between the increase in PMID and rate
of insertion of 6-SEP23 nAChRs (both are an approximate threefold increase) (Fig. 5, C and D). This sug
gests that the up-regulation of 623 nAChRs is caused
primarily by increased insertion into the PM, with no major
contribution from decreased internalization of receptors
from the PM (Lomazzo et al., 2011).
Despite the different PMIDs between 6-SEP23
and 6-SEP2 nAChRs, they showed the same rate of
insertion under basal conditions (12 ins/min). Therefore, the difference in the PM density of 6-SEP23
and 6-SEP2 nAChRs may be caused by differential
rates of internalization or stability of these nAChR subtypes at the PM, suggesting that the 3 nAChR subunit
may provide a stabilizing effect.
A KKK motif within the 3 M3–M4 loop governs the
up-regulation of 623 nAChRs

Our data suggest that 3 subunits markedly influence
the trafficking and dynamics of 62* nAChRs. We
next sought to identify specific motifs within 3 subunits
that may play a role in the trafficking and dynamics of
62* nAChRs.
We engineered a series of chimeras: (a) a chimera
with a 3 M3–M4 loop replacing the 2 M3–M4 loop in
a 2 subunit (23) and (b) a chimera with a 2 M3–M4
loop replacing the 3 M3–M4 loop in a 3 subunit (32)
(see Fig. S2). 6-SEP223, 6-SEP23, 6-SEP232,
and 6-SEP32 nAChRs exhibited typical TIRFM footprints and PM-ER fluorescence that were similar to 6SEP2* nAChRs (Fig. 6). 6-SEP223 and 6-SEP23

Visualization of membrane insertion events.
(A) TIRFM image of a Neuro-2a cell transfected with
6-SEP23 nAChRs and excited with a 488-nm laser.
Images were taken with a frame rate of 200 ms. (B1)
Frame directly preceding an insertion event at the PM.
(B2) Frame showing the insertion and (B3) the frame
directly after the observation of the insertion event.
The white circle marks the location of the insertion.
(C and D) Frequency of insertion events for 6-SEP2*
nAChRs without or with nicotine treatment (50 nM,
24 h) calculated as insertion events per minute (n = 4).
Bars, 10 µm. Data are mean values ± SEM. n.s., not significant; *, P < 0.05.
Figure 5.
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nAChRs up-regulated with 50 nM nicotine, whereas 6SEP32 and 6-SEP232 nAChRs showed either no
change or a decrease in the PMID with 50 nM nicotine,
suggesting that the 3 subunit M3–M4 domain specifically regulates nicotine-induced up-regulation but may
not control the basal trafficking of 6* nAChRs (Fig. 6,
A2 and B2).
Unique among nAChR subunits, the 3 nAChR subunit possesses a KKK motif within its M3–M4 loop. Dilysine trafficking motifs, including KKxx and KxKxx,
facilitate protein binding to COPI, a component of the
Golgi–ER retrograde transport machinery (Jackson
et al., 2012). Although these motifs typically occur at
cytoplasmic C termini, the KKK found in the 3 subunit
satisfies both of these consensus motifs. Thus, we hypothesized that the KKK may act as a COPI recognition site.
We mutated the 381KKK383 motif in the 3 M3–M4 loop
to 381AAA383 to create 23[AAA] and 3AAA nAChR subunits. Mutant nAChRs exhibited a typical TIRFM footprint and showed comparable overall nAChR expression
to WT receptors (Fig. 6, C and D). We observed a significant decrease in the number of ER resident 6SEP223[AAA] and 6-SEP23AAA nAChRs (Fig. 6, C1
and D1). In addition, the 6-SEP223[AAA] and 6SEP23AAA nAChRs did not increase the PMID when
treated with 50 nM nicotine (Fig. 5, C and D), suggesting that the KKK motif was essential for the nicotineinduced up-regulation of 6-SEP2* nAChRs. Similarly,
we found a 44% increase in peak ACh-induced currents
for 6-eGFP23 nAChRs after treatment with 50 nM
nicotine (24 h) but no increase for 6-eGFP23AAA

nAChRs (Fig. S3). 6-eGFP23 or 6-eGFP23AAA
nAChRs did not show a difference in ACh-induced currents under basal conditions. These results correlated with
the observed PMIDs of 6-SEP23 and 6-SEP23AAA
nAChRs (Fig. 6).
Nicotine up-regulates nAChRs by binding to and chaperoning ER-localized receptors, which are then trafficked
to the PM (Srinivasan et al., 2011). The formation of additional ERES with nicotine is a direct indicator of an
event immediately after the nAChR chaperoning process
(Srinivasan et al., 2011). To assess the effect of nicotine
on 623AAA nAChR chaperoning, we quantified the
formation of condensed ERES (Fig. 7, A and B). Neuro2a cells were cotransfected with either 6-eGFP23
or 6-eGFP23AAA nAChRs and Sec24D-mCherry
(a marker for active ERES) (Srinivasan et al., 2011). 50 nM
nicotine caused a significant (P < 0.005) threefold increase of ERES in 6-eGFP23 nAChRs but no change
in ERES with 6-eGFP23AAA nAChRs (Fig. 7 B).
The 3 KKK motif inhibits up-regulation by preventing
retrograde Golgi to ER nAChR transport

We observed a decrease in the ER density of 3-AAA
nAChRs compared with WT nAChRs (Fig. 6, C and D)
and hypothesized that loss of the KKK (COPI-binding
motif) disrupted trafficking between the Golgi and ER.
To test this hypothesis, we studied how WT and 3-AAA
nAChRs localized within the Golgi. Fig. 7 (C and D) shows
colocalization of 6-eGFP23 and 6-eGFP23AAA
nAChRs with the Golgi marker GalT-mCherry. 3AAA
subunits caused a significant increase in the Pearson

The 3 KKK motif participates in nAChR up-regulation. (A1, B1, C1, and D1) Representative TIRFM images of Neuro-2a cells
transfected with 6-SEP and cotransfected with combinations of 2, 23, 32, 23[AAA], and 3AAA subunits. 50 nM nicotine was added
24 h after transfection. Bars, 10 µm. (A2, B2, C2, and D2) PMID for nAChRs (n = 11–27). ***, P < 0.0001 (ANOVA).

Figure 6.
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correlation coefficient for 6-eGFP and GalT-mCherry
colocalization (Fig. 7 D1; P < 0.0001) and a significant
(P < 0.01) increase in the 6-eGFP23AAA nAChR density when compared with 6-eGFP23 nAChRs, within
the Golgi (Fig. 7 D2). Therefore, the removal of the
KKK motif increased the density of 623 nAChRs in
the Golgi compartment.
To determine whether COPI Golgi–ER trafficking is
deficient, we assessed colocalization by immunostaining
for endogenous COPI in Neuro-2a cells transfected
with 6-eGFP23 and 6-eGFP23AAA nAChRs (Fig. 7,
E, F1, and F2). We found that 6-eGFP23AAA nAChRs
exhibited a significant, twofold decrease in density in
COPI vesicles when compared with 6-eGFP23
nAChRs (Fig. 7 F1; P < 0.01). This was accompanied by
a significant decrease in the pixel-based Pearson correlation coefficient among WT and 3-AAA nAChRs (P <
0.0001; Fig. 7 F2). Despite this decrease, we observed no
difference in the 6-eGFP* whole-cell fluorescence
intensity between 6-eGFP23 nAChRs and 6eGFP23AAA nAChRs (20.2 ± 3.1 and 18.3 ± 4.8 RFUs
[millions], respectively). Thus, the potential contribution
from degradation is unlikely.

Upon treatment with 50 nM nicotine, we observed a
twofold increase in the 6-eGFP23 nAChR density in
COPI vesicles when compared with non-nicotine–treated
conditions. In contrast, there was no increase in 6eGFP23AAA nAChRs (Fig. 7 F1). This suggests that
after chronic nicotine treatment, an increase of 6*
nAChRs in COPI vesicles accompanies the up-regulation observed on the PM. Collectively, these data show
that a defect in the recognition between COPI vesicles
and 6-eGFP23AAA nAChRs results in decreased retrograde movement of these nAChRs back into the ER.
The COPI inhibitor CI-976 blocks up-regulation but not
basal trafficking of 623 and 42 nAChRs

Our data suggest that Golgi–ER cycling of 623
nAChRs is necessary for up-regulation during chronic
exposure to nicotine. Next, we investigated whether this
also applies to other subtypes. For these experiments,
we used CI-976, which inhibits COPI-mediated retrograde trafficking at concentrations ≥20 µM (Yang et al.,
2005, 2011). Inhibition of COPII vesicle budding occurs
at a somewhat higher concentration (50 µM) (Brown
et al., 2008).

3-AAA nAChRs show
increased density in Golgi despite
no change in ER export. Confocal
image of 6-eGFP23 and Sec24DmCherry (A), 6-eGFP23 with
Golgi marker GalT-mCherry (C),
and 6-eGFP23 nAChRs stained
for endogenous -COP (E). Quantification of: Sec24D fluorescence in
ERES per cell for 6-eGFP23WT
and 6-eGFP23AAA nAChRs (B)
(n = 21–31); Pearson correlation between 6-eGFP* and GalT-mCherry
fluorescence for 6-eGFP23WT
and 6-eGFP23AAA nAChRs (D1)
(n = 30–35); 6-eGFP* intensity in
Golgi for 6-eGFP23WT and 6eGFP23AAA nAChRs (D2) (n = 30–
35); 6-eGFP fluorescence in COPI
vesicles for 6-eGFP23WT and
6-eGFP23AAA nAChRs (F1) (n =
23–25); and Pearson correlation
for the colocalization of 6-eGFP*
fluorescence with COPI fluorescence in 6-eGFP23WT and 6eGFP23AAA nAChRs (F2) (n =
23–24). Bars, 5 µm. *, P < 0.01; **, P <
0.005; ***, P < 0.0001 (ANOVA).
Figure 7.
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First, we assessed the effects of 20 µM CI-976 on ERES
(Fig. S4 A). CI-976 did not affect the basal number of
ERES in 6-GFP23 nAChRs but did prevent the increase in ERES with chronic nicotine treatment (50 nM).
This is the same trend that was observed with 6GFP23AAA nAChRs (see Fig. 6 D2). With CI-976 treatment, we also noted a significant (P < 0.005) increase in
the 6-GFP density in the Golgi (Fig. S4 B) and a significant (P < 0.05) increase in the Pearson correlation coefficient for colocalization of 6-eGFP and GalT-mCherry
(Fig. S4 C). These data mimic the results seen with 6GFP23AAA nAChRs (Fig. 7) and suggest that CI-976
can be used to study the inhibition of Golgi–ER cycling
in nAChRs.
COPI may play a role in anterograde transport in addition to its role in retrograde transport (Yang et al.,
2011). We conducted experiments to determine whether
the concentration of CI-976 we used inhibited COPImediated anterograde traffic of nAChRs. We studied
44 and 42enhanced-ER-export (also called 42-DM
nAChRs), which both have a high rate of passage from
ER to the PM (Richards et al., 2011; Srinivasan et al.,
2011). We reasoned that if CI-976 reduced the PMID of

either 44 or 42-DM nAChRs, it would indicate an
inhibitory effect on COPI-mediated anterograde traffic.
We observed no change in the PMID of 44 or
42-DM nAChRs after CI-976 treatment (Fig. S5). We
also note (again) that COPI did not change the level of
basal ERES (Fig. S4 A), arguing against the idea that
exit from the ER is affected by CI-976. Collectively, these
data suggest that CI-976 effects are exerted on COPI’s
retrograde pathway only.
623 nAChRs treated with CI-976 produced similar trends compared to 623AAA nAChRs (compare
Figs. 6 D2 to 8 B1). As usual, 50 nM nicotine treatment
produced a significant (P < 0.005) increase in the PMID
of 6-SEP23 nAChRs (Fig. 8 B1). Treatment with
20 µM CI-976 alone did not differ from the basal conditions seen in 6-SEP23 nAChRs (no change in PMID),
but when cells were coexposed to CI-976 and nicotine,
up-regulation of 6-SEP23 nAChRs was blocked
(Fig. 8 B1). Previous analyses show that 100 nM nicotine
is an appropriate concentration for the study of 4SEP2 nAChR up-regulation (Richards et al., 2011;
Srinivasan et al., 2011). We observed a significant (P <
0.05) increase in the 4-SEP2 nAChR PMID with

Blocking Golgi–ER cycling prevents
up-regulation of nAChRs. (A) Representative
TIRFM images of 4-SEP2 (right) or 6SEP23 (left) nAChR subunits. Nicotine (50 nM
6-SEP23 nAChRs or 100 nM 4-SEP2
nAChRs) and/or 20 µM CI-796 were added 24 h
before imaging. Bars, 10 µm. Quantification of
PMID for 6-SEP23 nAChRs (B1) or 4-SEP2
nAChRs (B2) in Neuro-2a cells with drug treatments: no drug, nicotine, CI-976, or combined (n =
17–23). *, P < 0.05; ***, P < 0.0001 (ANOVA).
Figure 8.
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100 nM nicotine and, similar to our observations in 6SEP23 nAChRs, treatment of 4-SEP2 nAChRs with
CI-976 alone did not differ from basal conditions (no
change in PMID) (Fig. 8 B2). When both CI-976 and
nicotine were present with 4-SEP2 nAChRs, up-regulation was prevented (Fig. 8 B2). These results suggest
that a COPI-dependent process, related to Golgi–ER cycling, is necessary for the nicotine-induced up-regulation of 42 as well as 623 nAChRs.
NFRET measurements of the 623–COP interaction

We asked whether nAChRs and COPI display NFRET.
Neuro-2a cells were transfected with 6-mCherry, 2,
and 3 (WT and 3-AAA) nAChR subunits along with
COP-eGFP (Fig. 9 A). Fig. 9 A shows that NFRET
between 6-mCherry and COP-eGFP exhibited patterns similar to endogenous COP staining (see Fig. 7 E).
Evidently, 6-mCherry and COP-eGFP colocalize
within 100 Å.
We asked whether the 3-AAA mutation or CI-976 can
inhibit the interaction between 623 and COP.
nAChRs with the 3-AAA mutation consistently shifted
pixel-based NFRET amplitude distributions to lower values (Fig. 9, A–C). Treatment with CI-976 also consistently
shifted pixel-based NFRET amplitude distributions to
lower values (Fig. 9, A–C). Similarly, when we assigned an
NFRET value to each cell by calculating the average

NFRET of the cell’s nonzero FRET pixels, the NFRET
among cells was significantly decreased in the presence
of nAChRs with the 3-AAA mutation or treatment with
CI-976 (Fig. 9 C). In addition to NFRET, we used COPGFP fluorescence to demarcate ROI for COPI vesicles,
and then examined the density of 6* nAChRs in the
COPI ROI (as in Fig. 7 F1). 6-eGFP23AAA nAChRs (no
drug) and WT 6-eGFP23 nAChRs (treated with CI976) exhibited a significant decrease in their density
within COPI vesicles (Fig. 9 D; P < 0.005). This was accompanied by a significant decrease in the pixel-based
Pearson correlation coefficient (Fig. 9 E). Collectively,
these results demonstrate that disruption of the KKK
motif or inhibition of COPI destabilizes the interaction
between COPI and 623 nAChRs.
DISCUSSION
6* nAChRs up-regulate after chronic nicotine treatment

This paper documents the in vivo up-regulation of 6*
nAChR protein at a sustained nicotine concentration
comparable to that in human smokers. We found that
up-regulation occurs in the four major brain regions
that express 6-GFP nAChRs: VTA, SNc, medial habenula, and superior colliculus (see Figs. 1 and 2).
The 6 and 3 nAChR subunits have nearly identical
expression patterns in the brain, as reported by analysis

3-AAA nAChRs and CI-976
treatment decrease interaction between 6 and COPI. NFRET measurements were made using 6-mCherry
and COP-eGFP transfected in Neuro2a cells (along with 2 and 3wt or
3AAA subunits). (A) Representative
NFRET images between 6-mCherry
and COP-eGFP in Neuro-2a cells.
Bars, 10 µm. (B) Summed histograms
of pixel-based NFRET measurements,
representative of four independent
NFRET assays (n = 20 cells). C–E show
analysis of the same group of cells (n =
28 cells). (C) Another of the four experiments. Scatter-box plot for the
mean NFRET values of individual
cells. The larger black diamond ()
in the box plot represents the cellbased mean of each condition. (D) 6eGFP fluorescence in COPI vesicles
for 6-eGFP23AAA nAChRs and 6eGFP23WT nAChRs (without and
with 20 µM CI-976). (E) Pearson correlation for the colocalization of 6eGFP* fluorescence with COP-GFP
fluorescence (n = 28 cells). *, P < 0.05;
**, P < 0.01; ***, P < 0.005 (ANOVA).
Figure 9.
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of mRNA and autoradiography (Le Novère et al., 1996;
Azam et al., 2002; Baddick and Marks, 2011). In heterologous systems, 623 nAChRs show better function
(higher density on the PM, larger peak current response) than 62. Therefore, it is appropriate to study
effects of chronic nicotine on 62* nAChRs in the
context of coexpressed 3 subunits. We found that, at
concentrations mimicking the steady-state levels found
in human smokers and during nicotine replacement
therapy (50 nM nicotine), 6-SEP23 nAChRs up-regulate whereas 6-SEP2 nAChRs failed to up-regulate.
The 3 subunit thus appears necessary for the up-regulation of 6-SEP2* nAChRs. This agrees well with
Tumkosit et al. (2006), who showed that 3 nAChR
subunits promote nicotine-induced up-regulation of
6* nAChRs.
Our observations of 6* up-regulation agree with
some previously published work (Parker et al., 2004;
Perez et al., 2008; Walsh et al., 2008). Other studies
found that chronic nicotine treatment leads to a decrease

in the contribution of 6* nAChRs, as identified by binding or dopamine release assays (Lai et al., 2005; Perry
et al., 2007; Exley et al., 2013). Several factors may contribute to these disparate findings. First, the up-regulation
of 6* nAChRs we observed was in midbrain (VTA and
SNc) dopaminergic neurons, whereas the studies showing a decrease in 6* nAChR contribution were completed in the striatal regions. We have confirmed
previously that 6-GFP* nAChRs in the VTA and SNc are
localized exclusively in dopaminergic neurons (Mackey
et al., 2012). The difference in striatal (down-regulation)
and midbrain (up-regulation) may be explained by a
different population of nAChRs (64*, 6[non4]*,
63*, and/or 6[non3]*). Perez et al. (2008) have
shown that although 6(non4)* nAChRs up-regulate,
64* nAChRs down-regulate. We, along with others
(Tumkosit et al., 2006), have shown that 6* nAChRs
may require the 3 subunit to up-regulate. Therefore,
the population of nAChRs residing in the somata of
midbrain dopaminergic neurons may be composed of

Figure 10. A schematic representation of
selective pharmacological chaperoning of
nAChRs in response to chronic nicotine.
(A) Nicotine interconverts within milliseconds
between the protonated membrane-impermeant form and the neutral membrane-permeant form. The latter enters cells and enters
the ER (red arrow). Here, the charged form
pharmacologically chaperones nAChRs so
that increased numbers exit toward the Golgi
via the COPII pathway, eventually resulting
in receptor up-regulation at the PM. Thus,
pharmacological chaperoning by nicotine is
thought to underlie the process of nAChR
up-regulation by chronic nicotine. (B) This
study finds that nicotine-mediated up-regulation also depends on the COPI machinery
involved in ER to Golgi and Golgi to ER transport of nAChRs. One possible explanation
for the COPI dependence is that nicotine
enters additional organelles and binds more
extensively than previously thought within
the early exocytic pathway, shown by the additional red arrows leading to both COPI and
COPII vesicles, ERGIC, and cis-Golgi. See
also the animation, “Nicotine Up-regulates
nAChRs”: http://www.jgp.org/cgi/content/
full/jgp.201311102/DC2.
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more 6(non4)3* nAChRs than 64* or 6(non3)*
nAChRs. However, there may be more 64* or
6(non3)* nAChRs on these neurons’ dopaminergic
terminals in the striatum and accumbens. This is supported by a report that there are more 64* nAChRs
on dopaminergic terminals (in striatum and accumbens) than there are on dopaminergic cell bodies (in VTA
and SNc) (Champtiaux et al., 2003).
Second, differing concentrations of nicotine were
used in the different studies. The doses of nicotine we
used in mice (2 mg/kg/h and 0.4 mg/kg/h) produce
plasma concentrations of <500 and <100 nM nicotine,
respectively (Marks et al., 2004). Perry et al. (2007) used
a dose (6 mg/kg/day) in rats that produces >500 nM
plasma nicotine (Nguyen et al., 2004). Our data show
that 500 nM nicotine decreased the density of 6* nAChRs
on the PM (Fig. 4, D and F). Therefore, the differences
observed in our current work and in that of others (Lai
et al., 2005; Perry et al., 2007; Exley et al., 2013) may be
caused by the concentration of nicotine used.
The KKK motif of 3 nAChR subunit suggests that a COPImediated retrograde pathway participates in up-regulation

A KKK motif appears in the M3–M4 intracellular loop
of the 3 nAChR subunit. COPI binds to di-lysine motifs
(KKxx or KxKxx) (Jackson et al., 2012; Ma and Goldberg,
2013), and the KKK of the 3 subunit satisfies both motifs. Measurements of FRET between 623 nAChRs
and COP indicate that the two molecules approach
with 100 Å, and this interaction is decreased by mutating the 3-KKK sequence to 3-AAA (Fig. 9). This suggests that one of these di-lysine motifs in 3 mediates a
direct interaction between nAChRs and COPI.
We hypothesized that COPI likely plays a role in the
retrograde transport of 623 nAChRs from the Golgi
back to the ER. 6* nAChRs with a 3-AAA in place of
3-KKK failed to up-regulate on the PM in the presence
of nicotine. We found that the ER localization of the
6-SEP23AAA nAChRs was decreased compared with
6-SEP23 nAChRs, suggesting that the 3-AAA motif
changed the distribution of nAChRs among organelles
in the early secretory pathway. Indeed, we found that
the 6-SEP23AAA nAChRs had a significantly higher
localization within the Golgi than the 6-SEP23
nAChRs (Fig. 7, C, D1, and D2).
When we add the fact that the number of ERES does
not differ between the 623 and 623AAA nAChRs in
basal conditions (e.g., no nicotine) (Fig. 7, A and B), we
can conclude that the export (via COPII vesicles) of
nAChRs is not affected. Thus, 623AAA nAChRs are
exported from the ER at a rate similar to that of 623
nAChRs. Because export (COPII mediated) is not affected,
this suggests that retrieval (COPI mediated) is responsible for the disrupted trafficking. This was confirmed
when we observed significantly fewer 623AAA nAChRs
in COPI vesicles when compared with 623 nAChRs


(see Fig. 7, E, F1, and F2). Furthermore, 3-AAA nAChRs
shifted the NFRET distribution to lower values compared with WT nAChRs (see Fig. 9). Collectively, these
data suggest that the disruption of the KKK motif results in deficient retrograde transport of nAChRs between the Golgi and ER. Although one cannot draw
specific conclusions about the locus of interference in
the cyclic processes involving ER, COPII, cis-Golgi, and
COPI (Orci et al., 1997), the data suggest that this disrupted cycling from the Golgi back to the ER prevents
up-regulation during exposure to nicotine.
A COPI-dependent process, such as Golgi–ER cycling, is
necessary for the up-regulation of nAChRs

We asked whether Golgi–ER cycling plays a role in the
other case of nAChRs (42) that up-regulate at smokingrelevant concentrations of nicotine. Because the 3 KKK
motif is unique in nAChR subunits, we exploited a more
general inhibitor approach, CI-976, to block COPI function. On 623 nAChRs, CI-976 produced results that
resembled the pattern observed for 3-WT and 3-AAA
nAChRs (compare Figs. 8 B1 with 6 D2). Inhibiting
Golgi–ER cycling prevented up-regulation of 623
and 42 nAChRs after nicotine treatment. This suggests
that the cycling of nAChRs between the Golgi and ER is
necessary for the up-regulation of nAChRs on the PM.
Previous reports indicate that nAChR up-regulation is
initiated within intracellular compartments and that the
locus is partially in the ER (see Fig. 10) (Kuryatov et al.,
2005; Sallette et al., 2005; Lester et al., 2009; Miwa et al.,
2011; Srinivasan et al., 2011). The data presented here
suggest novel aspects of the up-regulation of nAChRs,
related to general observations that secretory pathways
have both regulated and constitutive components. The
increased nAChR density on the PM results from increased ER export of 623 nAChRs (increase in ERES/
COPII, leading to increased insertion events). Previous
data show that this also occurs in 42 nAChRs (Richards
et al., 2011; Srinivasan et al., 2011) (depicted in Fig. 10).
We show here that chronic nicotine also increases the
number of nAChRs in COPI vesicles (Fig. 7 F1). This
suggests that in addition to an increase in ER export,
there is also an increase of retrograde movement of
nAChRs from the Golgi to the ER. Possibly, 623 and
42 nAChRs are continually cycled between the ER and
Golgi through COPI and COPII. This cycling maintains
a population of nAChRs in the ER that may be necessary for up-regulation. In the absence of nicotine, disruption of Golgi–ER cycling (either through the 3-AAA
mutants or use of CI-976) does not affect PM nAChR
density (Figs. 8 B1 and 6 D2). However, when Golgi–ER
cycling is inhibited and nicotine is present, nicotine can
not produce up-regulated PM nAChRs.
How does nicotine exploit a COPI process to up-regulate PM nAChRs? There are three nonmutually exclusive possibilities. (1) Decreased retrieval of nAChRs
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from the Golgi produces an increased number of Golgiresident nAChRs but a reduced number of ER-resident
nAChRs. Individual nAChRs therefore spend a smaller
fraction of time in the ER. Perhaps this renders them
less available for pharmacological chaperoning by nicotine (Fig. 10 A). Such chaperoning seems to be relatively inefficient, even though it takes place at nicotine
concentrations 10–100 times lower than that required
for activation of PM nAChRs. This inefficiency could
occur because binding of nicotine must await the dissociation of a competing endogenous chaperone protein
such as lynx1 (Miwa et al., 2012). (2) Pharmacological
chaperoning by nicotine does stabilize pentameric
nAChRs in the ER (Whiteaker et al., 1998; Sallette et al.,
2005) but is nonetheless a pathological process that
could block or prevent one or more modifications required for efficient exit from the Golgi to the PM. If the
nAChRs chaperoned by nicotine fail to pass the quality
control checks in the Golgi, they would be targeted for
retrieval back to the ER via a COPI-dependent process.
(3) An intriguing possibility is that nicotine may enter
additional organelles within the early exocytotic pathway. Nicotine might remain bound to nAChRs while the
nAChRs reside in COPI and/or COPII vesicles (Fig. 10 B).
Processes related to pharmacological chaperoning,
termed “matchmaking,” “escorting,” or “abduction,”
might occur in these vesicles (Lester et al., 2012). Because the ER and cis-Golgi have nearly neutral lumenal
pH, acid trapping of nicotine (Jia et al., 2003; Lester
et al., 2009) probably plays little role in the processes
studied here.
Golgi–ER cycling as a new mechanistic target
for drug discovery

Discovery of the role played by Golgi–ER cycling in both
623 and 42 nAChRs may eventually provide additional avenues for nicotine addiction therapies. A hypothetical small molecule designed to bind to the KKK
and disrupt COPI binding would prevent the Golgi–ER
cycling in a manner similar to observations in this work.
This inhibition of Golgi–ER cycling would prevent the
up-regulation of 3-containing nAChRs and may produce effects similar to many antagonists that have shown
clinical promise (Watkins et al., 1999; Rauhut et al.,
2003; Yoshimura et al., 2007). In the search for potential
therapeutics, the selective expression pattern of 623
nAChRs to just a few neuronal populations would render
the targeting of 3 more selective than a drug that inhibits Golgi–ER cycling in general.
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